Logo
x

Search

Subscribe Now

Astellas

Astellas Reports MAA Withdrawn for Avacincaptad Pegol (ACP) in the EU

Astellas Reports MAA Withdrawn for Avacincaptad Pegol (ACP) in the EU

  • October 28, 2024
Astellas Reports the US FDA’s Approval of Vyloy (Zolbetuximab-clzb) to Treat Advanced G/GEJ Cancer

Astellas Reports the US FDA’s Approval of Vyloy (Zolbetuximab-clzb) to Treat Advanced G/GEJ Cancer

  • October 21, 2024
Astellas Join Forces with AviadoBio for AVB-101 Gene Therapy Targeting Frontotemporal Dementia and Other Indications

Astellas Join Forces with AviadoBio for AVB-101 Gene Therapy Targeting Frontotemporal Dementia and Other Indications

  • October 9, 2024
Astellas’ Vyloy (Zolbetuximab) Plus Chemotherapy Gains the EC’s Approval for Advanced Gastric and Gastroesophageal Junction Cancer

Astellas’ Vyloy (Zolbetuximab) Plus Chemotherapy Gains the EC’s Approval for Advanced Gastric and Gastroesophageal Junction Cancer

  • September 24, 2024
Astellas Reports the US FDA Listing of DIGITIVA to Manage Heart Failure

Astellas Reports the US FDA Listing of DIGITIVA to Manage Heart Failure

  • September 19, 2024
Astellas Begins the P-III Clinical Evaluation of Fezolinetant for Vasomotor Symptoms (VMS) Among Breast Cancer Patients

Astellas Begins the P-III Clinical Evaluation of Fezolinetant for Vasomotor Symptoms (VMS) Among Breast Cancer Patients

  • August 27, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.